Literature DB >> 9163262

[Treament of morphine-induced constipation with oral naloxone].

L Latasch1, M Zimmermann, B Eberhardt, I Jurna.   

Abstract

INTRODUCTION: Almost all patients treated with opioids suffer from constipation. Numerous laxatives are used to overcome the problem, but none has yet been found to yield favourable results in all patients. Several studies have attempted to reverse opioid-induced constipation by the use of oral naloxone. Experiments carried out in rats showed that morphine-induced constipation is reduced by oral naloxone without impairment of antinociception [4]. However, evaluation of clinical studies reveals that there is uncertainty about the dosage regimen (the daily dose of naloxone ranged from 0.5% to about 60% that of morphine) and a lack of larger numbers of patients studied.
METHODS: Fifteen patients suffering from opioid-induced constipation participated in the present study. Constipation had been present for 5 to 14 days despite the use of laxatives. According to the results obtained in the animal experiments [4], it was originally planned to administer oral naloxone at a dose ratio of 1:1 with respect to morphine on day 1 and 2; reducing it on day 3 and 4 to one-half and then to one-fourth of the initial dose on day 5 and 6.
RESULTS: Twelve patients experienced a strong laxative effect with spontaneous bowel evacuation 1 to 4 h after the first intake of oral naloxone. Three patients had no laxative effects even after repeated doses. Eleven of the 15 patients reported an average loss of 10%-15% of analgesia after oral naloxone as measured by visual analogue scales. Increasing the morphine dose by about 15% restored the previous level of analgesia without reappearance of constipation. Eight of the 12 patients having a laxative effect experienced abdominal cramps, and therefore, the total dose of naloxone was reduced on day 2 to 2%-15% of that originally planned; this dose still produced a laxative effect. Four of the 15 patients had a withdrawal syndrome. A single dose of morphine equivalent to their daily morphine intake abolished the symptoms. DISCUSSION: The medical history of the 3 patients in whom naloxone failed to abolish constipation revealed neurological disturbances. Treatment of these patients included the use of neuroleptics, antiemetics, and other drugs. In this context, it should be noted that oral naloxone can be expected to abolish only opioid-induced constipation. In conclusion, it was found that the treatment of opioid-induced constipation by administration of oral naloxone produced positive results. A controlled study will show, whether the side effects can be minimized by reducing the naloxone dose.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9163262     DOI: 10.1007/s001010050390

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  9 in total

1.  [Strong opioids and constipation].

Authors:  A Schwarzer; F Nauck; E Klaschik
Journal:  Schmerz       Date:  2005-06       Impact factor: 1.107

Review 2.  Constipation in people prescribed opioids.

Authors:  Sam H Ahmedzai; Jason Boland
Journal:  BMJ Clin Evid       Date:  2010-04-06

Review 3.  [Opioid-induced bowel dysfunction: a literature analysis on pathophysiology and treatment].

Authors:  Jürgen Osterbrink; Ute Haas
Journal:  Wien Med Wochenschr       Date:  2008

4.  Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials.

Authors:  Oliver Löwenstein; Petra Leyendecker; Eberhard A Lux; Mark Blagden; Karen H Simpson; Michael Hopp; Björn Bosse; Karen Reimer
Journal:  BMC Clin Pharmacol       Date:  2010-09-29

Review 5.  Constipation--modern laxative therapy.

Authors:  E Klaschik; F Nauck; C Ostgathe
Journal:  Support Care Cancer       Date:  2003-09-20       Impact factor: 3.603

Review 6.  Constipation: opioid antagonists in people prescribed opioids.

Authors:  Sam H Ahmedzai; Jason W Boland
Journal:  BMJ Clin Evid       Date:  2015-09-11

7.  Recent advances in the use of opioids for cancer pain.

Authors:  Joanne Droney; Julia Riley
Journal:  J Pain Res       Date:  2009-09-23       Impact factor: 3.133

8.  Cannabinoid CB2 Receptor Activation Attenuates Fentanyl-Induced Respiratory Depression.

Authors:  Carmen A Zavala; Ana C Thomaz; Vishakh Iyer; Ken Mackie; Andrea G Hohmann
Journal:  Cannabis Cannabinoid Res       Date:  2020-10-21

9.  Randomized placebo-controlled study of intravenous methylnaltrexone in postoperative ileus.

Authors:  Eugene R Viscusi; James P Rathmell; Alessandro Fichera; Sander R Binderow; Robert J Israel; Frank L Galasso; Darryl Penenberg; Tong J Gan
Journal:  J Drug Assess       Date:  2013-08-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.